SCYNEXIS (SCYX) Competitors

SCYNEXIS (NASDAQ:SCYX) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Does the media favor SCYX or MRNS?

In the previous week, Marinus Pharmaceuticals had 6 more articles in the media than SCYNEXIS. MarketBeat recorded 12 mentions for Marinus Pharmaceuticals and 6 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.97 beat Marinus Pharmaceuticals' score of -0.01 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marinus Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has preferable valuation & earnings, SCYX or MRNS?

SCYNEXIS has higher revenue and earnings than Marinus Pharmaceuticals. Marinus Pharmaceuticals is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$140.38M	0.75	$67.04M	$2.04	1.36
Marinus Pharmaceuticals	$28.29M	2.58	-$141.40M	-$2.64	-0.50

Does the MarketBeat Community prefer SCYX or MRNS?

SCYNEXIS received 79 more outperform votes than Marinus Pharmaceuticals when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 69.27% of users gave Marinus Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
SCYNEXIS	Outperform Votes 505 70.24%	Underperform Votes 214 29.76%
Marinus Pharmaceuticals	Outperform Votes 426 69.27%	Underperform Votes 189 30.73%

Do institutionals and insiders hold more shares of SCYX or MRNS?

54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 4.4% of SCYNEXIS shares are owned by company insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Is SCYX or MRNS more profitable?

SCYNEXIS has a net margin of 72.18% compared to Marinus Pharmaceuticals' net margin of -513.80%. SCYNEXIS's return on equity of 112.89% beat Marinus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	72.18%	112.89%	68.17%
Marinus Pharmaceuticals	-513.80%	-518.13%	-81.85%

Which has more risk and volatility, SCYX or MRNS?

SCYNEXIS has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Do analysts recommend SCYX or MRNS?

SCYNEXIS currently has a consensus target price of $15.00, suggesting a potential upside of 441.52%. Marinus Pharmaceuticals has a consensus target price of $13.79, suggesting a potential upside of 936.52%. Given Marinus Pharmaceuticals' higher probable upside, analysts clearly believe Marinus Pharmaceuticals is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Marinus Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

SCYNEXIS beats Marinus Pharmaceuticals on 12 of the 18 factors compared between the two stocks.